Firms aim to bolster ProteoTech’s alpha-synuclein program.
GlaxoSmithKline (GSK) has decided to help ProteoTech advance work in its alpha-synuclein therapeutic program. The companies aim to identify small molecules against misfolded proteins to treat Parkinson disease and other synucleinopathies.
ProteoTech’s lead small molecule, Synuclere™, targets alpha-synuclein aggregation and is currently in late preclinical stages of development. Initial support for this program was funded over a four-year period by the Michael J. Fox Foundation for Parkinson’s Research.
ProteoTech is a private drug development company located in the Seattle, WA. Besides the Synuclere program, ProteoTech is developing Exebryl-1® for the treatment of diseases caused by beta-amyloid protein and tau protein aggregates and fibrils, like Alzheimer disease.
Additionally, the firm is in early clinical studies with Systebryl™ for the treatment of systemic AA amyloidosis. ProteoTech is also in late preclinical development for a small peptide (Pepticlere™) for the treatment of Alzheimer disease beta-amyloid protein aggregates.
